구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Atorvastatin |
Overview Company | Chong Kun Dang Pharmaceutical |
Overview Modality | CGT |
Overview Target | Breast Cancer |
Overview Indication | Breast Cancer; Heart Disease |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | targeted metabolomics identified circulating metabolites of the branched-chain amino acid (BCAA) pathway |
MoA Biomarker | Biomarker Discovery Study |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Comparison of pharmacokinetics and safety of fixed-dose versus loose combination of atorvastatin/fenofibrate 10/145 mg in healthy Korean participants.. Dyslipidemia is a risk factor for cardiovascular disease. Atorvastatin and fenofibrate are co-administered to treat mixed dyslipidemia, a subtype requiring long-term control of low-density lipoprotein cholesterol and triglycerides; fixed-dose combi… |
Clinical Safety signal | Comparison of pharmacokinetics and safety of fixed-dose versus loose combination of atorvastatin/fenofibrate 10/145 mg in healthy Korean participants.. Dyslipidemia is a risk factor for cardiovascular disease. Atorvastatin and fenofibrate are co-administered to treat mixed dyslipidemia, a subtype requiring long-term control of low-density lipoprotein cholesterol and triglycerides; fixed-dose combi… |
Clinical Program phase | PHASE_2 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Atorvastatin |
Overview Company | Chong Kun Dang Pharmaceutical |
Overview Modality | CGT |
Overview Target | Breast Cancer |
Overview Indication | Breast Cancer; Heart Disease |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
MoA Mechanism | targeted metabolomics identified circulating metabolites of the branched-chain amino acid (BCAA) pathway |
MoA Biomarker | Biomarker Discovery Study |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse |
Toxicology Major finding | Comparison of pharmacokinetics and safety of fixed-dose versus loose combination of atorvastatin/fenofibrate 10/145 mg in healthy Korean participants.. Dyslipidemia is a risk factor for cardiovascular disease. Atorvastatin and fenofibrate are co-administered to treat mixed dyslipidemia, a subtype requiring long-term control of low-density lipoprotein cholesterol and triglycerides; fixed-dose combi… |
Clinical Safety signal | Comparison of pharmacokinetics and safety of fixed-dose versus loose combination of atorvastatin/fenofibrate 10/145 mg in healthy Korean participants.. Dyslipidemia is a risk factor for cardiovascular disease. Atorvastatin and fenofibrate are co-administered to treat mixed dyslipidemia, a subtype requiring long-term control of low-density lipoprotein cholesterol and triglycerides; fixed-dose combi… |
Clinical Program phase | PHASE_2 |
추천 비교
추천 비교